Xichun Hu - Concepedia

Author

Xichun Hu

Fudan University Shanghai Cancer Center ORCID

Also Known As

Hu Xichun, Hu, Xichun, Juan J. Gu, XICHUN HU, Xi-Chun Hu, Xi-chun Hu, Xichun Hu, Xi‐Chun Hu

260

Publications

4.5K

Citations

H-Index

Concepts

All Affiliations

Fudan University Shanghai Cancer Center Shanghai Medical College of Fudan University Fudan University Sun Yat-sen University Zhejiang Cancer Hospital

About

Xichun Hu is an author at Fudan University Shanghai Cancer Center specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	22	1.1K
2	Cell Biology	6	6	157
3	Health Sciences	2	2	91
4	Biochemistry	2	2	50
5	Engineering	1	1	34

Xichun Hu

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer Xichun Hu, Jian Zhang, Binghe Xu, International Journal of Cancer	2014	267
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial Zefei Jiang, Wei Li, Xichun Hu, The Lancet Oncology Breast OncologyMedicinePharmacologyClinical TrialsBreast Cancer	2019	261
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer Xichun Hu, Jun Cao, Wenwei Hu, BMC Cancer	2014	233
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial Binghe Xu, Qingyuan Zhang, Pin Zhang, Nature Medicine Breast OncologyMedicinePharmacologyBreast CancerPharmacotherapy	2021	152
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib Leiping Wang, Qunling Zhang, Jian Zhang, BMC Cancer	2011	145
Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial Peng Yuan, Xichun Hu, Tao Sun, European Journal of Cancer	2019	86
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Pin Zhang, Qingyuan Zhang, Zhongsheng Tong, The Lancet Oncology Breast OncologyHealth SciencesMedicinePharmacologyClinical Trials	2023	79
Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy Minhao Fan, Jian Zhang, Zhonghua Wang, Breast Cancer Research and Treatment HypertensionAdvanced Breast CancerAngiogenesisBreast OncologyMedicine	2013	74
Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway Ting Li, Qunling Zhang, Jian Zhang, BMC Cancer	2014	73
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer Jian Zhang, Zhonghua Wang, Xichun Hu, International Journal of Cancer	2014	72

Page 1